183 related articles for article (PubMed ID: 11116285)
1. Lobaplatin: a new antitumour platinum drug.
McKeage MJ
Expert Opin Investig Drugs; 2001 Jan; 10(1):119-28. PubMed ID: 11116285
[TBL] [Abstract][Full Text] [Related]
2. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
Gietema JA; Veldhuis GJ; Guchelaar HJ; Willemse PH; Uges DR; Cats A; Boonstra H; van der Graaf WT; Sleijfer DT; de Vries EG
Br J Cancer; 1995 Jun; 71(6):1302-7. PubMed ID: 7779728
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
Gietema JA; de Vries EG; Sleijfer DT; Willemse PH; Guchelaar HJ; Uges DR; Aulenbacher P; Voegeli R; Mulder NH
Br J Cancer; 1993 Feb; 67(2):396-401. PubMed ID: 8431374
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
5. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
6. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
7. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
8. Lobaplatin: D 19466.
Drugs R D; 2003; 4(6):369-72. PubMed ID: 14584968
[TBL] [Abstract][Full Text] [Related]
9. Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
Chen L; Cao H; Yu C; Feng Y
Fundam Clin Pharmacol; 2018 Oct; 32(5):548-557. PubMed ID: 29733466
[TBL] [Abstract][Full Text] [Related]
10. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.
Engel JB; Martens T; Hahne JC; Häusler SF; Krockenberger M; Segerer S; Djakovic A; Meyer S; Dietl J; Wischhusen J; Honig A
Anticancer Drugs; 2012 Apr; 23(4):426-36. PubMed ID: 22314264
[TBL] [Abstract][Full Text] [Related]
11. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
Kavanagh JJ; Edwards CL; Freedman RS; Finnegan MB; Balat O; Tresukosol D; Burk K; Loechner S; Hord M; Franklin JL
Gynecol Oncol; 1995 Jul; 58(1):106-9. PubMed ID: 7789874
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion.
Gietema JA; Guchelaar HJ; de Vries EG; Aulenbacher P; Sleijfer DT; Mulder NH
Anticancer Drugs; 1993 Feb; 4(1):51-5. PubMed ID: 8457715
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio.
Du L; Fei Z; Song S; Wei N
Biomed Pharmacother; 2017 Nov; 95():447-452. PubMed ID: 28865364
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo.
Zhou Z; Jiang H; Xia J; Zhang J
Int J Oncol; 2020 Sep; 57(3):697-706. PubMed ID: 32582992
[TBL] [Abstract][Full Text] [Related]
16. The antitumor effect of lobaplatin against Ishikawa endometrial cancer cells in vitro and in vivo.
He J; Zhang H
Biomed Pharmacother; 2019 Jun; 114():108762. PubMed ID: 30925454
[TBL] [Abstract][Full Text] [Related]
17. Lobaplatin arrests cell cycle progression, induces apoptosis and alters the proteome in human cervical cancer cell Line CaSki.
Li X; Ran L; Fang W; Wang D
Biomed Pharmacother; 2014 Apr; 68(3):291-7. PubMed ID: 24239273
[TBL] [Abstract][Full Text] [Related]
18. Lobaplatin induces pyroptosis through regulating cIAP1/2, Ripoptosome and ROS in nasopharyngeal carcinoma.
Chen Z; Xu G; Wu D; Wu S; Gong L; Li Z; Luo G; Hu J; Chen J; Huang X; Chen C; Jiang Z; Li X
Biochem Pharmacol; 2020 Jul; 177():114023. PubMed ID: 32413426
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
20. Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE.
Wang Z; Tang X; Zhang Y; Qi R; Li Z; Zhang K; Liu Z; Yang X
Biomed Pharmacother; 2012 Apr; 66(3):161-6. PubMed ID: 22425181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
